IBRX — ImmunityBio, Inc. Stock Price, Chart & AI Report

Negative May 26, 2026 • 20:00 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX

Pomerantz Law Firm has filed class action lawsuits against ImmunityBio, Inc., New Era Energy & Digital, Inc., and Vital Farms, Inc. for alleged securities fraud and unlawful business practices. The primary case involves ImmunityBio, which faced an FDA warning letter on March 24, 2026, for continuing to promote its bladder-cancer drug Anktiva in a misleading manner despite previous warnings. The disclosure triggered a 21.12% stock price decline. Investors have until May 26, 2026, to request Lead Plaintiff status.

IBRX NUAI NUAIW VITL class action lawsuit securities fraud FDA warning letter misleading promotion

Sentiment note

Company received FDA warning letter for continuing misleading promotion of Anktiva drug despite previous warnings. Stock fell 21.12% on the news. Class action lawsuit filed for alleged securities fraud and unlawful business practices.

Negative May 25, 2026 • 23:22 UTC GlobeNewswire Inc. • Rosen Law Firm

IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

Rosen Law Firm reminds ImmunityBio investors of the May 26, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements about Anktiva's capabilities and ImmunityBio's business operations. Investors who purchased securities between January 19, 2026 and March 24, 2026 may be entitled to compensation.

IBRX securities class action lead plaintiff deadline false statements investor losses Anktiva misleading disclosures

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding Anktiva's capabilities and the company's business operations, resulting in investor losses.

Negative May 25, 2026 • 13:48 UTC GlobeNewswire Inc. • The Schall Law Firm

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its Anktiva drug capabilities, causing investor losses when the truth was revealed.

IBRX securities fraud class action lawsuit ImmunityBio Anktiva drug false statements investor losses Securities Exchange Act

Sentiment note

The company is the subject of a securities fraud lawsuit for making false and misleading statements about its Anktiva drug capabilities, resulting in investor losses. This represents serious regulatory and legal violations that damage investor confidence and shareholder value.

Negative May 22, 2026 • 22:11 UTC GlobeNewswire Inc. • Rosen Law Firm

IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

Rosen Law Firm announces securities class action lawsuits against ImmunityBio, Inc. and other companies for allegedly making false and misleading statements. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the May 26, 2026 deadline. According to the lawsuit, ImmunityBio's defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in false statements about the company's business and prospects.

IBRX ADMA SRAD securities class action false statements lead plaintiff investor losses contingency fee

Sentiment note

Company is subject to securities class action lawsuit alleging material misstatements and overstatement of product capabilities by leadership, resulting in investor losses during the Class Period (January 19 - March 24, 2026).

Negative May 22, 2026 • 16:48 UTC GlobeNewswire Inc. • Hagens Berman

IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens Berman

ImmunityBio (IBRX) is facing a securities class action lawsuit after the FDA issued a warning letter regarding misleading efficacy claims made by executive chairman Dr. Patrick Soon-Shiong about the company's drug Anktiva. The FDA determined that promotional materials falsely suggested Anktiva could treat all cancers, when it is only approved for non-muscle invasive bladder cancer. The announcement caused IBRX shares to plunge over 21% on March 24, 2026, erasing nearly $2 billion in market capitalization. Hagens Berman is investigating claims that ImmunityBio intentionally misled investors.

IBRX securities class action FDA warning letter misleading efficacy claims Anktiva cancer treatment stock price decline investor losses

Sentiment note

The company faces a securities class action lawsuit following FDA warnings about misleading promotional claims regarding Anktiva's efficacy. The stock declined over 21% and the company lost nearly $2 billion in market capitalization due to allegations of intentional investor deception about the drug's capabilities.

Negative May 20, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) alleging that company defendants made materially false and misleading statements regarding Anktiva's capabilities and the company's business prospects. The lawsuit covers investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026. The lead plaintiff deadline is May 26, 2026.

IBRX class action lawsuit securities fraud ImmunityBio Anktiva investor harm false statements lead plaintiff

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging material misstatements and omissions regarding product capabilities and business prospects, which directly harms investor confidence and shareholder value.

Positive May 20, 2026 • 12:49 UTC Benzinga • Vandana Singh

ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug

ImmunityBio's stock rose 8.12% in premarket trading after the FDA accepted its supplemental Biologics License Application (sBLA) for ANKTIVA in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The FDA assigned a PDUFA target action date of January 6, 2027. The Phase 2/3 QUILT 3.032 trial demonstrated strong efficacy with a 12-month disease-free survival rate of 58.2% and 96.0% disease-specific survival at 36 months.

IBRX FDA approval ANKTIVA bladder cancer NMIBC BCG-unresponsive sBLA clinical trial

Sentiment note

FDA acceptance of sBLA filing represents significant regulatory progress for the company's product pipeline. Strong clinical trial data (58.2% 12-month DFS, 96.0% 36-month DSS) and stock price appreciation of 8.12% in premarket trading indicate positive market reception and advancement toward expanded market approval.

Positive May 19, 2026 • 16:57 UTC Benzinga • Vandana Singh

ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies

ImmunityBio presented comparative analyses showing its ANKTIVA plus BCG combination achieved higher complete response rates (69.7%) against nadofaragene firadenovec-vncg (53.4%) and longer response duration (22.1 vs 9.7 months). Against TAR-200, ANKTIVA showed comparable efficacy with significantly fewer adverse events (61.7% vs 83.5%), representing a 68% reduction in treatment-related side effects for BCG-unresponsive bladder cancer patients.

IBRX JNJ ANKTIVA bladder cancer BCG-unresponsive clinical trial comparative analysis complete response rate

Sentiment note

Company demonstrated superior efficacy and safety profiles for ANKTIVA in head-to-head comparisons against FDA-approved competitors, with higher response rates, longer duration, and significantly fewer adverse events. However, stock declined 3.94% at publication, suggesting market skepticism or profit-taking despite positive clinical data.

Negative May 18, 2026 • 21:40 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

A class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) in the U.S. District Court for the Central District of California. The lawsuit alleges that defendants made false and misleading statements regarding Anktiva's capabilities and the company's business operations during the Class Period (January 19, 2026 - March 24, 2026). Investors who purchased ImmunityBio securities during this period and suffered losses have until May 26, 2026, to apply to be appointed as lead plaintiff.

IBRX class action lawsuit securities fraud false statements Anktiva investor losses lead plaintiff deadline

Sentiment note

The company is the subject of a class action lawsuit alleging material misstatements about product capabilities (Anktiva) and business operations, resulting in investor losses. This represents significant legal and reputational risk.

Positive May 18, 2026 • 14:20 UTC Benzinga • Vandana Singh

ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership

ImmunityBio announced an exclusive U.S. development and supply agreement with Japan BCG Laboratory for Tokyo-172 BCG to treat bladder cancer, backed by positive Phase 3 trial data showing non-inferiority to TICE BCG. The company also secured five U.S. patents for its ANKTIVA plus BCG platform through 2035. Despite the news, IBRX shares fell 1.13% to $7.88 on Monday.

IBRX bladder cancer BCG treatment Phase 3 trial patent protection ANKTIVA Tokyo-172 BCG FDA approval

Sentiment note

The company secured an exclusive U.S. partnership for a promising bladder cancer treatment with positive Phase 3 data showing non-inferiority to existing therapy, expanded patent protection through 2035, and is positioned to address a decade-long BCG shortage. These are significant strategic and clinical achievements that strengthen the company's competitive position.

Negative May 15, 2026 • 13:00 UTC GlobeNewswire Inc. • The Gross Law Firm

IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for ImmunityBio, Inc. (NASDAQ: IBRX) regarding a securities class action lawsuit. The complaint alleges that defendants issued materially false and misleading statements about Anktiva's capabilities during the class period of January 19, 2026 to March 24, 2026. Shareholders who purchased shares during this period are encouraged to register by the May 26, 2026 deadline.

IBRX securities class action ImmunityBio materially false statements Anktiva shareholder lawsuit investor losses

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misstatements and misleading disclosures regarding product capabilities, which typically results in stock price decline and investor losses.

Negative May 14, 2026 • 18:45 UTC GlobeNewswire Inc. • Law Offices Of Howard G. Smith

DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Atara Biotherapeutics (ATRA), Coty Inc. (COTY), Super Micro Computer (SMCI), and ImmunityBio (IBRX). The lawsuits allege that defendants made false or misleading statements regarding their business operations and prospects. Lead plaintiff deadlines range from May 22-26, 2026.

ATRA COTY SMCI IBRX securities fraud class action lawsuit lead plaintiff false statements

Sentiment note

Alleged material overstatement of Anktiva's capabilities by defendant Soon-Shiong, resulting in misleading statements about company prospects.